NCT06340347View on ClinicalTrials.gov

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Liver Diseases
Interventions
DRUG

Osivelotor

"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"

Trial Locations (3)

19107

Thomas Jefferson University-Pharmacology, Physiology and Cancer Biology, Philadelphia

33603

Genesis Clinical Research, LLC, Tampa

92630

Orange County Research Center, Lake Forest

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06340347 - A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function | Biotech Hunter | Biotech Hunter